|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02269 WUXI BIO
Nominal 
50.650 +0.150 (+0.297%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 11,787,238 | 18.426% | 21,790,018 | 18,675,371 | 17,034,255 | 15,268,660 |
| Cost of Sales | (6,338,919) | 11.202% | (11,771,506) | (11,024,551) | (10,206,354) | (8,544,646) |
| Gross Profit | 5,448,319 | 28.110% | 10,018,512 | 7,650,820 | 6,827,901 | 6,724,014 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (106,739) | -20.251% | (205,333) | (151,779) | (319,970) | (258,525) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 3,419,292 | 2.740% | 7,256,907 | 4,834,398 | 4,173,803 | 5,357,771 | |
| Taxation | (503,083) | -11.970% | (1,523,680) | (889,027) | (603,179) | (807,865) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (476,396) | 14.149% | (824,884) | (589,290) | (170,895) | (129,620) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,439,813 | 4.298% | 4,908,343 | 3,356,081 | 3,399,729 | 4,420,286 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (161,170) | 75.540% | (251,523) | (192,779) | (60,690) | (43,093) |
| Depreciation & Amortisation | 936,645 | 9.617% | 1,740,740 | 1,659,205 | 1,385,662 | 1,042,990 |
| Directors' Emoluments | -- | -- | -- | 135,735 | 132,940 | 105,824 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 60.000 | 3.448% | 122.000 | 82.000 | 82.000 | 106.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.574 | 1.278 | 1.121 | 1.328 |
| NBV per share ($) | 11.602 | -- | 11.430 | 10.185 | 9.473 | 8.295 |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,439,813 |
| %Change | 4.298% |
| EPS / (LPS) | RMB 0.600 |
| NBV Per Share (¥) | RMB 11.602 |